Authors
|
Year
|
Title
|
Journal and link to the article
|
| Bulten-Ducuing et al. |
2023 |
The therapeutic potential of psychedelics: the European regulatory perspective |
The Lancet |
Holze et al.
|
2022 |
Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects.
|
Neuropsychopharmacology |
McCulloch et al.
|
2022 |
Psychedelic resting-state neuroimaging: a review and perspective on balancing replication and novel analyses.
|
Neuroscience & Biobehavioral Reviews
|
Carhart-Harris et al.
|
2021 |
Trial of psilocybin versus escitalopram for depression.
|
New England Journal of Medicine
|
Vizeli et al.
|
2021 |
Genetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis.
|
Scientific Reports
|
Stenbæk et al.
|
2020 |
Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans.
|
Journal of Psychopharmacology
|
Madsen et al.
|
2019 |
Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. |
Neuropsychopharmacology
|
Preller et al.
|
2018 |
Phenomenology, structure, and dynamic of psychedelic states.
|
Current Topics in Behavioral Neurosciences
|
Preller et al.
|
2018 |
Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor.
|
eLife
|
Kuypers et al.
|
2016 |
Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking.
|
Psychopharmacology
|
Páleníček et al.
|
2011 |
Electroencephalographic spectral and coherence analysis of ketamine in rats: correlation with behavioral effects and pharmacokinetics.
|
Neuropsychobiology
|
